OOIR: Observatory of International Research

Papers

(The TQCC of Drug Metabolism and Pharmacokinetics is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
Difference in the lipid nanoparticle technology employed in three approved siRNA (Patisiran) and mRNA (COVID-19 vaccine) drugs	116
Adenovirus vector-based vaccine for infectious diseases	61
Identification of biomarkers to diagnose diseases and find adverse drug reactions by metabolomics	36
Recent advances in lipid nanoparticles for delivery of nucleic acid, mRNA, and gene editing-based therapeutics	34
Pharmacokinetic functions of human induced pluripotent stem cell-derived small intestinal epithelial cells	33
Quantitative and targeted proteomics-based identification and validation of drug efficacy biomarkers	20
Current progress in identifying endogenous biomarker candidates for drug transporter phenotyping and their potential application to drug development	19
An improved TK-NOG mouse as a novel platform for humanized liver that overcomes limitations in both male and female animals	19
Pharmacogenomics research and its clinical implementation in Thailand: Lessons learned from the resource-limited settings	18
Suppressive effect of quercetin against bleomycin-induced epithelial-mesenchymal transition in alveolar epithelial cells	15
Ideal pharmacokinetic profile of dotinurad as a selective urate reabsorption inhibitor	15
Cellular uptake properties of lamotrigine in human placental cell lines: Investigation of involvement of organic cation transporters (SLC22A1–5)	13
Functional characterization of monocarboxylate transporter 12 (SLC16A12/MCT12) as a facilitative creatine transporter	13
Exosomes: Breast cancer-derived extracellular vesicles; recent key findings and technologies in disease progression, diagnostics, and cancer targeting	12
Characterization of covalent binding of tyrosine kinase inhibitors to plasma proteins	12
Classification of drugs for evaluating drug interaction in drug development and clinical management	12
Transport via Niemann-Pick C1 Like 1 contributes to the intestinal absorption of ubiquinone	12
Species differences in liver accumulation and metabolism of nucleotide prodrug sofosbuvir	11
Cytochrome P450-dependent drug oxidation activities and their expression levels in liver microsomes of chimeric TK-NOG mice with humanized livers	11
Delivery of small interfering RNAs by nanovesicles for cancer therapy	11
Species difference in brain penetration of P-gp and BCRP substrates among monkey, dog and mouse	10
Genetic variants of flavin-containing monooxygenase 3 (FMO3) in Japanese subjects identified by phenotyping for trimethylaminuria and found in a database of genome resources	10
Versatile applicability of a grid-based CYP3A4 Template to understand the interacting mechanisms with the small-size ligands; part 3 of CYP3A4 Template study	10
Feature importance of machine learning prediction models shows structurally active part and important physicochemical features in drug design	10
Post-transcriptional regulation of OATP2B1 transporter by a microRNA, miR-24	10

Comparison of the inhibitory effects of azole antifungals on cytochrome P450 3A4 genetic variants	9
Development of template systems for ligand interactions of CYP3A5 and CYP3A7 and their distinctions from CYP3A4 template	9
Oxidative metabolism and pharmacokinetics of the EGFR inhibitor BIBX1382 in chimeric NOG-TKm30 mice transplanted with human hepatocytes	8
Quantitative analysis of mRNA expression levels of aldo-keto reductase and short-chain dehydrogenase/reductase isoforms in human livers	8
WDR23 regulates the expression of Nrf2-driven drug-metabolizing enzymes	8
Synthetic molecule libraries for nucleic acid delivery: Design parameters in cationic/ionizable lipids and polymers	8
Application of comprehensive lipidomics to biomarker research on adverse drug reactions	8
Recent progress in the use of microRNAs as biomarkers for drug-induced toxicities in contrast to traditional biomarkers: A comparative review	8
The utility of CYP3A activity endogenous markers for evaluating drug-drug interaction between sildenafil and CYP3A inhibitors in healthy subjects	8
A physiologically based pharmacokinetic/pharmacodynamic modeling approach for drug-drug interaction evaluation of warfarin enantiomers with sorafenib	7
A series of simple detection systems for genetic variants of flavin-containing monooxygenase 3 (FMO3) with impaired function in Japanese subjects	7
Mathematical modeling analysis of hepatic uric acid disposition using human sandwich-cultured hepatocytes	7
Applications of a grid-based CYP3A4 Template system to understand the interacting mechanisms of large-size ligands; part 4 of CYP3A4 Template study	7
Associations of HLA and drug-metabolizing enzyme genes in co-trimoxazole-induced severe cutaneous adverse reactions	7
PreMetabo: An in silico phase I and II drug metabolism prediction platform	7
Refined CYP2E1∗ Template∗∗ system to decipher the ligand-interactions	7
Increased plasma concentrations of an antidyslipidemic drug pemafibrate co-administered with rifampicin or cyclosporine A in cynomolgus monkeys genotyped for the organic anion transporting polypeptide	7
Food effects on gastrointestinal physiology and drug absorption	7
Establishment of MDR1-knockout human induced pluripotent stem cell line	7
Extrapolation for a pharmacokinetic model for acetaminophen from adults to neonates: A Latin Hypercube Sampling analysis	6
Dual kinetics of OATP2B1: Inhibitory potency and pH-dependence of OATP2B1 inhibitors	6
Plausible drug interaction between cyclophosphamide and voriconazole via inhibition of CYP2B6	6
Differences in transport function of the human and rat orthologue of the Organic Anion Transporting Polypeptide 2B1 (OATP2B1)	6
High hepatic and plasma exposures of atorvastatin in subjects harboring impaired cytochrome P450 3A4∗16 modeled after virtual administrations and possibly associated with statin intolerance found in t	6
Gene and oligonucleotide delivery via micro- and nanobubbles by ultrasound exposure	6
Urinary metabolic markers reflect on hepatic, not intestinal, CYP3A activity in healthy subjects	5
A family study of compound variants of flavin-containing monooxygenase 3 (FMO3) in Japanese subjects found by urinary phenotyping for trimethylaminuria	5
Inhibitory effects of non-steroidal anti-inflammatory drugs on human liver microsomal morphine glucuronidation: Implications for drug-drug interaction liability	5
Feasibility of physiologically based pharmacokinetic simulations for assessing pediatric patients after accidental drug ingestion: A case study of a 1.4-year-old girl who ingested alprazolam	5
Utility of Göttingen minipigs for the prediction of human pharmacokinetic profiles after intravenous drug administration	5
Intestinal microbiota-mediated biotransformations alter the pharmacokinetics of the major metabolites of azathioprine in rats after oral administration	5
Multivalent cation and polycation polymer preparations influence pharmacokinetics of dolutegravir via chelation-type drug interactions	5
Diclofenac potentiates the antitumor effect of cisplatin in a xenograft mouse model transplanted with cisplatin-resistant cells without enhancing cisplatin-induced nephrotoxicity	5
Epicatechin gallate and epigallocatechin gallate are potent inhibitors of human arylacetamide deacetylase	5
Predicting drug metabolism and pharmacokinetics features of in-house compounds by a hybrid machine-learning model	5
BTK-inhibitor drug covalent binding to lysine in human serum albumin using LC-MS/MS	5
Physiologically based pharmacokinetic modeling of altered tizanidine systemic exposure by CYP1A2 modulation: Impact of drug-drug interactions and cigarette consumption	5